NCT Number: NCT05293496
Phase: Phase 1
Trial Summary: Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab. The study is designed to characterize safety, tolerability, pharmacokinetics ( – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MacroGenics
Acronym:
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives